Anti-amyloid drugs like Leqembi and Kisunla are among the first FDA-approved treatments for early-stage Alzheimer’s disease. But these breakthroughs come with a tradeoff: Up…
A person who struggles with tasks they’ve been doing for years or asks the same question over and over again may be showing the…
When ancient Greek soldiers laid their mythical siege upon the city of Troy, they struggled to break through the city’s impenetrable walls. To finally…
European regulators rejected Lilly’s Kisunla citing the number of ARIA-related deaths in its Phase 3 trial. The company will look to appeal the decision….
There currently no cure or treatment that can completely halt or reverse Alzheimer’s pathology in the brain. One of the biggest obstacles: Even after…
When Eisai announced in a press release this week that they’d secured FDA approval for an Alzheimer’s drug dosage change, it seemed like a…
Would you still participate in an Alzheimer’s clinical trial if you found out that because of your genetics, you were more vulnerable to serious…
In just a single year of studying a rare genetic mutation in a single family in the Arctic reaches of remote northern Sweden, a…
Drugmaker Alzheon is currently running clinical trials on a new disease-modifying Alzheimer’s treatment: valiltramiprosate, or ALZ-801. While, like the new buzzy new Alzheimer’s monoclonal…
Diagnosed with Alzheimer’s and one of the relative few who has gotten a prescription for the new, disease-modifying anti-amyloid drug Leqembi? If you live…
The Food and Drug Administration has decided to postpone its decision on the approval of Eli Lilly’s candidate Alzheimer’s drug, donanemab. The delay has…
Alzheimer’s disease affects millions of people worldwide, and as the world’s population ages, that number is going up. But, the exact cause of Alzheimer’s…
Neurologists and Alzheimer’s research experts explain the side effect known as ARIA — or brain bleeds — associated with the use of anti-amyloid monoclonal antibody…
Biogen renounced ownership of their controversial anti-Alzheimer’s drug Aduhelm after years of dismal sales. The company is also halting an ongoing clinical trial set…
On July 6, 2023, the U.S. Food and Drug Administration fully approved the Alzheimer’s drug Leqembi (generic name lecanemab), a monoclonal antibody drug for…